Maturing antibody–drug conjugate pipeline hits 30

  title={Maturing antibody–drug conjugate pipeline hits 30},
  author={Asher Mullard},
  journal={Nature Reviews Drug Discovery},
  • Asher Mullard
  • Published 30 April 2013
  • Biology, Chemistry, Medicine
  • Nature Reviews Drug Discovery
Driven by recent clinical breakthroughs and technological progress, 30 antibody–drug conjugates against over 24 targets are now in trials for blood cancers and solid tumours. 
Maturing antibody–drug conjugate pipeline hits 30
The text has been updated to clarify Stuart Lutzker's affiliation and the PDB has been corrected to PBD.
Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
Leveraging Physiology for Precision Drug Delivery
A large number of drug delivery platforms have been devised ranging from macro- to micro-based systems, but how these are implemented and how they are implemented are still in the early stages.
HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc03257a
Self-immolative linker and a disulfide trigger are used to design macromolecular prodrugs of panobinostat as efficacious HIV latency reversing agents.
Emerging classes of armed antibody therapeutics against cancer
Some of the most advanced preclinical and clinical activities in the field of armed antibodies are reviewed and a personal perspective on the opportunities and challenges associated with the use of this type of anti-cancer therapeutics is presented.
Antibody-drug conjugates: an evolving approach for melanoma treatment.
The successes of FDA-approved ADCs to date compared to the ongoing efforts of melanoma-targeting ADCs are explored to distinguish how ADCs may better impact individuals with malignancies such as melanoma.
Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).
The use of next generation maleimides for the construction of a potent antibody-drug conjugate (ADC) via functional disulfide bridging with excellent stability in blood serum and the ADC shows excellent potency and cancer cell selectivity in vitro.
Antibody drug conjugates: Progress, pitfalls, and promises.
The main components in the design of antibody drug conjugates, improvements made, and lessons learned over two decades of research are reviewed, as well as the future of third generation ADCs.
Antibody-drug conjugates—an emerging class of cancer treatment
This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.
Antibody-drug conjugates in cancer therapy—filling in the potholes that lie ahead
A number of biological and technical pitfalls exist that will need to be overcome if AntibodyDrug Conjugates are to fulfil their full therapeutic potential, and the more important of these challenges will be discussed.